Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TAD1 Risk Assessment for Cardiac Amyloidosis With Evuzamitide (TRACE)

NCT07538518 is registered in ClinicalTrials.gov with Lorena Saelices as lead sponsor.

NCT NCT07538518
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07538518 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TAD1 Risk Assessment for Cardiac Amyloidosis With Evuzamitide (TRACE)
Lead sponsor
Lorena Saelices
Phase
Observational
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
April 1, 2028
Enrollment
25 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

amyloidogenic transthyretin (attr) amyloidosis, cardiac amyloidosis